The effect of aminoguanidine (AG) and pyridoxamine (PM) on ageing human cortical bone

**Objectives**

Advanced glycation end-products (AGEs) are a post-translational modification of collagen that form spontaneously in the skeletal matrix due to the presence of reducing sugars, such as glucose. The accumulation of AGEs leads to collagen cross-linking, which adversely affects bone quality and has been shown to play a major role in fracture risk. Thus, intervening in the formation and accumulation of AGEs may be a viable means of protecting bone quality.

**Methods**

An in vitro model was used to examine the efficacy of two AGE-inhibitors, aminoguanidine (AG) and pyridoxamine (PM), on ageing human cortical bone. Mid-diaphyseal tibial cortical bone segments were obtained from female cadavers (n = 20, age range: 57 years to 97 years) and randomly subjected to one of four treatments: control; glucose only; glucose and AG; or glucose and PM. Following treatment, each specimen underwent mechanical testing under physiological conditions via reference point indentation, and AGEs were quantified by fluorescence.

**Results**

Treatment with AG and PM showed a significant decrease in AGE content versus control groups, as well as a significant decrease in the change in indentation distance, a reliable parameter for analyzing bone strength, via two-way analysis of variance (ANOVA) (p < 0.05).

**Conclusions**

The data suggest that AG and PM prevent AGE formation and subsequent biomechanical degradation in vitro. Modulation of AGEs may help to identify novel therapeutic targets to mitigate bone quality deterioration, especially deterioration due to ageing and in AGE-susceptible populations (e.g. diabetics).

**Cite this article:** Bone Joint Res 2018;7:105–110.

**Keywords:** Bone quality, Ageing, Osteoporosis, Non-enzymatic glycation, Cortical bone
The results represent a potential therapy for increased fracture resistance due to osteoporosis.

These in vitro results require further investigation with in vivo studies.

Introduction

Osteoporosis is a common skeletal condition that affects more than 200 million people worldwide. The causes of osteoporosis are numerous and multifaceted, and include genetics, vitamin D levels, hormone levels, and lifestyle.

Skeletal fractures as a consequence of osteoporosis lead to increases in the morbidity and mortality rates among men and women. In particular, approximately 30% of all postmenopausal women in Europe and the United States have osteoporosis, and are therefore susceptible to incapacitating fractures.

Osteoporosis is marked by declining bone mineral density as well as declining bone quality. Advanced glycation end-products (AGEs) are among the bone quality changes that result from post-translational modifications of collagen (90% of the organic phase in bone), which form spontaneously in the skeletal matrix in the presence of reducing sugars, such as glucose. This process is called non-enzymatic glycation (NEG). Advanced glycation end-products can form cross-linkages that have detrimental effects, but the mechanism of formation and the effect of these cross-links on diabetes and bone fragility are still under extensive investigation.

Advanced glycation end-products reduce the propensity of bone to resist fracture, and the accumulation of AGEs in bone causes stiffening of the type I collagen network. This increasing number of collagen cross-linkages alters the micro- and nanoscale energy dissipation mechanisms, which increases the likelihood of bone fractures.

Given their adverse mechanical consequences, inhibition of AGEs may be a viable strategy for the restoration of bone strength and the prevention of fractures, particularly in postmenopausal women who are susceptible to reduced oestrogen-mediated decline in bone quality and diabetic patients who are susceptible to high blood glucose levels. Aminoguanidine (AG) and pyridoxamine (PM) are used as AGE formation inhibitors and have been shown to decrease AGE formation in diabetic rats. While previous studies have confirmed that AG and PM play a significant role in the assembly process of AGEs in vitro, the effect of these two inhibitors on AGE accumulation and subsequent biomechanical degradation in human cortical bone remains relatively unknown. We therefore used an in vitro model to investigate the preventative effects of AG and PM on cortical bone AGE content and their subsequent effects on bone strength.

Materials and Methods

Study sample. Cortical bone segments were taken from the mid-diaphyseal tibia of 20 fresh-frozen female cadavers (mean age 79 years, sem 11; range 57 to 97) for this study. Female cadavers were selected to investigate AGE inhibition in the population that is susceptible to hormonal changes throughout menopause that may lead to osteoporosis. These de-identified cadavers were obtained from the Washington University Tissue Donor Program and the Anatomical Education Program of Indiana University. No live human subjects were involved in this research study (IRB Waiver, Washington University Medical Center).

We randomly assigned identical segments from each donor (n = 20) to one of four experimental groups: negative control (C), positive control glucose (G), or two inhibitor treatment groups. A summary of the treatment groups is shown in Table I.

A base solution for glycation was prepared in Hank’s buffered salt solution (Gibco 14170112; Thermo Fisher Scientific, Waltham, Massachusetts) with a final concentration of 25 mM 6-Aminocaproic acid (A2504; Sigma-Aldrich Corp., St. Louis, Missouri), 5 mM Benzanamide (12072; Sigma-Aldrich), 10 mM N-ethylmaleimide (E3876; Sigma-Aldrich), 10 mM HEPES (H3375; Sigma-Aldrich) buffer, and 100 μg/ml Streptomycin sulfate salt (S6501; Sigma-Aldrich). One quarter of this solution was aliquoted for the negative control group. Dextrose (D-(+) -Glucose) (G8270; Sigma-Aldrich) was added to the remainder of the buffer solution to create a 100 mM glucose solution.

Specimens were completely submerged in solution with five times the volume of bone at 50°C. Previous studies have shown that this temperature mimics three months of ageing per two weeks of incubation. The temperature was maintained at 50°C and, if necessary, the pH of the solution was adjusted and maintained between 7.2 and 7.6 using 0.5 N NaOH or 0.5 N HCl. It has been previously demonstrated that this incubation protocol does not cause loss of mineral content in bone.

AGE formation inhibitors. From the 100 mM glucose buffer solution, two thirds were set aside for testing the efficacy of AGE-inhibitors co-incubated with glucose. One third of the glucose solution was set aside to make a 400 μM AG hemisulfate salt (A7009; Sigma) solution (approximately 800 mg/kg of tissue), an effective AG concentration for selective prevention of AGE formation. The remaining 100 mM glucose solution was used to make a 100 μM PM dihydrochloride (P9380; Sigma) solution (approximately 400 mg/kg of tissue), which previous studies have shown is a nontoxic and effective concentration of PM.

AGE analysis. Four bone segments measuring approximately 4 mm × 4 mm × 4 mm were cut and isolated from each donor (n = 20) under wet conditions using a Smart Cut diamond wafering saw (UKAM Industrial, Valencia, California). Each segment was allocated to a treatment...
370 nm excitation and 440 nm emission wavelengths. BioTek Instruments, Inc., Winooski, Vermont) using fluorescence in a multimode plate reader (Cytation 5; at a wavelength of 560 nm. Protein assays used to quantify both aGEs and collagen content were conducted by serially diluted hydroxyproline via absorbance properties chloramine-T colorimetric assay and standardized using amounts of collagen in each sample as determined by a

The absolute bone content was then normalized to the standards, in order to determine the content of aGEs by triplicate, along with serially diluted quinine sulfate at 120°C for three hours. Hydrolysates were plated in standards, in order to determine the content of aGEs by triplicate, along with serially diluted quinine sulfate at 120°C for three hours. Hydrolysates were plated in phosphate-buffered saline (PBS)-soaked gauze at -20°C until hydrolysis.

Each segment underwent acid hydrolysis in 12 N HCl at 120°C for three hours. Hydrolysates were plated in triplicate, along with serially diluted quinine sulfate standards, in order to determine the content of aGEs by fluorescence in a multimode plate reader (Cytation 5; BioTek Instruments, Inc., Winooski, Vermont) using 370 nm excitation and 440 nm emission wavelengths. The absolute bone content was then normalized to the amount of collagen in each sample as determined by a chloramine-T colorimetric assay and standardized using serially diluted hydroxyproline via absorbance properties at a wavelength of 560 nm. Protein assays used to quantify both aGEs and collagen content were conducted by the lead author (OA) blinded of treatment group.

**Mechanical testing via reference point indentation.** To assess the effect of AG and PM treatment on the biomechanical properties (strength) of bone, four cortical bone segments measuring approximately 4 mm × 4 mm × 4 cm were taken from the same donor cortical bone samples as the AGE analysis (n = 20) and randomly assigned to an experimental group. The protocol for incubation solutions used for studying AGEs was replicated. Solutions were changed every other day and all samples were incubated at 50°C in an oven, maintained at a pH in the range of 7.2 to 7.6. After three days, each segment was isolated from its solution and cut in half, allowing the other half to continue incubation for a total of seven days. Three-day incubation segments with dimensions 4 mm × 4 mm × 2 cm were tested for mechanical properties using a reference point indentation (RPI) system (BioDent; Active Life Scientific, Inc., Santa Barbara, California) on the medial-anterior surface of each segment. The same mechanical testing procedure was performed on the seven-day incubation segments.

In this approach, a small reference probe rests on the surface of the bone while an indentation probe initiates a microcrack and subsequently propagates the crack through repeated indentations. This methodology has been shown to correlate with crack growth toughness, a known component of whole-bone fragility. Indentation was performed for 20 cycles with a peak force of 10 N. From the force-displacement curves, the parameter indentation distance increase (IDI) was obtained, which is the difference in indentation depth between the first and 20th cycle. This parameter, which has been shown to correlate with biomechanical properties of bone such as strength and failure load, was used exclusively to assess the strength of the bone segment, where an inverse relationship exists between IDI and bone strength. Additionally, three indentation sites were tested per segment for repeated measure, separated by a distance of 5 mm. The mean of three measurements per segment was used for statistical analysis.

**Statistical analysis.** The data are presented as the mean and standard error of the mean. Statistical analyses were conducted using Prism 6 (GraphPad Software Inc., La Jolla, California). Experimental groups were analyzed and compared via two-way analysis of variance (ANOVA) testing. The results were considered significant with a probability of error of 5% or lower.

**Results**

AGE accumulation was observed as a uniform colour change of the bone specimen from white to brownish-yellow. For the seven-day group, AGE content, defined as nanograms of quinine sulfate fluorescence per milligram of collagen, increased markedly (p < 0.05) from control to glycosylated groups (Fig. 1). Aminoguanidine treatment significantly decreased the mean AGEs concentration compared with the positive control (G) (p < 0.05).

Aminoguanidine and PM treatment both significantly inhibited AGE accumulation compared with glucose treatment alone after seven days of analysis as measured.

---

**Table 1. Outline of control and treatment groups**

| Negative control (C) | Positive control glucose (G) | Aminoguanidine treatment group (AG) | Pyridoxamine treatment group (PM) |
|----------------------|-----------------------------|-------------------------------------|----------------------------------|
| Buffersolution at 50°C | 100 mM glucose buffer solution at 50°C | 400 μM AG and 100 mM glucose buffer solution at 50°C | 100 μM PM and 100 mM glucose buffer solution at 50°C |

**Fig. 1**

Advanced glycation end-product (AGE) content (measured by ng quinine/mg collagen) across all treatment groups after seven days of incubation. White, control (C); orange, glucose only (G); cross-hatched, aminoguanidine co-incubated with glucose (AG); vertical stripes, pyridoxamine co-incubated with glucose (PM) (n = 20; *p < 0.05, two-way analysis of variance (ANOVA)).

---

**VOL. 7, NO. 1, JANUARY 2018**
by the percentage change in AGE concentration from the control (Fig. 2).

Biomechanical testing via RPI strongly supports the results of the AGE analysis. After three days of glucose treatment, IDI increased significantly compared with the control group (p < 0.0001) (Fig. 3). After a week of incubation, a statistically significant difference was still observed between control and glucose groups (p < 0.05). These results verify the biomechanical decline in bone quality observed due to glucose treatment alone.

Two-way ANOVA with multiple comparisons revealed a significant positive effect of treatment with AG and PM on IDI after both three and seven days (Fig. 4). Aminoguanidine and PM treatment both significantly reduce IDI or improve bone strength, compared with glucose treatment alone, after three and seven days (p < 0.01). There was no statistically significant difference between control, AG, and PM treatment groups after both three and seven days. These results suggest that AG and PM prevent bone mechanical degradation, likely due to NEG.

Increased AGE content corresponds with increased IDI (or reduced crack growth toughness), controlled for bone mineral density by calculating the mean of the parameter for each experimental group (Fig. 5). AG and PM mitigate increased AGE content and IDI compared with the glucose group alone.

**Discussion**

One of the relevant age-related changes in bone quality is the accumulation of AGEs in the organic matrix of bone. At the macro level, AGEs directly affect bone by reducing its biomechanical properties. Advanced glycation end-products may also affect the remodelling of bone, allowing microdamage and AGEs to accumulate at a greater rate. Here we show the ability of AG and PM to improve the quality of existing bone matrix by cleaving established AGE cross-links known to accumulate with ageing, disease, and the antiresorptive treatment of osteoporosis.

Properties of an effective AGE-inhibitor include the ability to trap highly reactive intermediates of AGEs formation in the glycation pathway, to arrest the formation of AGEs at the carbonyl stress stage or after formation of reactive protein adducts, and to be selective (i.e. not interfere with sugar metabolism). Two viable treatment options are AG and PM. Both are potent AGE-inhibitors that have been shown to prevent diabetic complications including nephropathy, neuropathy, and vasculopathy. Aminoguanidine traps reactive dicarbonyls, impeding their conversion to AGEs, as well as preventing cross-link formation and inhibiting free radical formation. Its limitations, however, include its short half-life (one hour) and its toxicity to humans in high concentrations. While the results show that AG is effective at preventing AGEs formation, the treatment conditions used included super-physiological concentrations of the compound. As a naturally occurring antioxidant, PM inhibits the synthesis of AGEs from glycated proteins by reducing highly reactive carbonyl intermediates in the glycation pathway. Pyridoxamine has been shown to increase cardiovascular compliance and thus relieve hypertension. We observed that PM has similar effects to those of AG; it relieves AGE cross-linking and improves the mechanical properties of bone. Additionally, the concentration of PM used in this study previously has been shown to be nontoxic and effective in diabetic rats.

The mean of the control AGE content was 12.41 ng quinine/mg collagen (SEM = 5.22) across all 20 donors over an age range of between 57 and 97 years (Fig. 1). Our study did not find age to be a significant predictor of AGE accumulation, which could be attributable to the fact that the donors were all above the age of 50, suggesting that significant in vivo AGE accumulation occurs throughout life. Previous studies have shown that age is a
significant predictor of AGE accumulation in 60 donors over an age range of 2.5 to 103 years. It is noteworthy that after seven days of incubation, AG inhibits mean AGEs concentration in contrast to the glucose treatment group alone (Fig. 1). Pyridoxamine shows potential as an AGE-inhibitor but statistical analysis was not significant between PM and glucose treatment alone; this could be due to the sample size for the AGEs quantification assay, where a larger sample size would produce more power that may show PM as a more promising AGE inhibitor. In Figure 2, we use the same data to receive additional empirical support that AG and PM reduce AGE content as a percentage change of the control compared with the glucose only group (*p < 0.05, **p < 0.01) after seven days. Results from bone microindentation testing further support these results. We focus on the parameter IDI as an indicator of bone strength, with an increase in IDI indicative of increased bone fragility or reduced crack growth toughness. Glucose treatment significantly increases IDI compared with the control after three days (p < 0.05) (Fig. 3). It is particularly notable that there is no statistically significant difference between the control and inhibitor treatment groups after three and seven days, which may indicate that treatment with AG or PM mitigates the harmful effects of glucose on crack growth toughness (Fig. 4). Additionally, AG and PM treatment reduces IDI (or increased crack growth toughness) after both three and seven days compared with treatment with glucose alone (Fig. 4). These findings are valuable because they complement the AGE analysis data with biomechanical support at the bone-tissue macro level.

We are interested in the relationship between microlevel bone properties such as AGE content and macrolevel biomechanical bone properties such as IDI. Previous research has shown that AGE content correlates with IDI. The data in Figure 5 suggest that, as hypothesized, an increase in AGE content corresponds with an increase in IDI (or reduced crack growth toughness), controlled for bone mineral density by calculating the mean of the parameter for each experimental group. Thus, this analysis provides support for the use of AG and PM as effective inhibitors of AGE accumulation and subsequent biomechanical degradation measured via RPI.

This study examined the preventative effects of AG and PM on AGE formation in human cortical bone. One major limitation of this work is that it was conducted in vitro. In order to prove feasibility for human use, in vivo animal and human studies need to be performed. It is noteworthy that AG administration to rats was effective in preventing diabetes-induced formation of fluorescent AGEs and cross-linking of arterial wall connective tissue protein in vivo. Additionally, another in vivo study showed that PM reduces oxidative stress and AGE formation in diabetic rats. In light of these previous studies and the in vitro results presented in this study, we suggest that AG and PM warrant further investigation for inhibiting AGE accumulation in bone, improving bone quality, and preventing debilitating and expensive complications of diabetes and ageing.

In summary, glucose increases AGE formation in human cortical bone due to NEG. The results suggest that AG and PM prevent AGE formation and subsequent biomechanical degradation, warranting further investigation into the safety and efficacy of these treatments. Studying the accumulation of AGEs will help identify novel therapeutic targets to treat bone quality deterioration, especially in AGE-susceptible populations such as diabetics.
References

1. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-289.
2. Gómez-de-Tejada Romero M-J, Navarro Rodríguez MD, Saavedra Santana P, et al. Prevalence of osteoporosis, vertebral fractures and hypovitaminosis D in postmenopausal women living in a rural environment. Maturitas 2014;77:282-286.
3. Singer BR, McLauchlan GJ, Robinson CM, Christie J. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 1998;80-B:243-248.
4. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:879-882.
5. Cooper C, Atkinson EJ, O’Fallon WM, Melton LJ III. Age-related changes in the plasticity and toughness of human cortical bone at multiple length scales. J Bone Miner Res 2010;25:1877-1885.
6. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-1936.
7. Donnelly E. Methods for assessing bone quality: a review. Clin Orthop Relat Res 2011;469:2128-2138.
8. Sanghani-Kerali A, Coathup M, Samazidi S, et al. Osteoporosis and ageing affects the migration of stem cells and this is ameliorated by transfection with CXCRA. Bone Joint Res 2017;6:385-396.
9. Paul RG, Bailey AJ. Glycation of collagen: the basis of its central role in the late complications of ageing and diabetes. Int J Biochem Cell Biol 1996;28:1297-1310.
10. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:128-146.
11. Farr JR, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res 2014;29:787-795.
12. Abraham AC, Agarwalla A, Yadavalli A, Liu JY, Tang SY. Microstructural and compositional contributions towards the mechanical behavior of aging human bone measured by cyclic and impact reference point indentation. Bone 2016;87:37-43.
13. Vashishth D, Gibson GJ, Khoury JI, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001;28:195-201.
14. Tang SY, Zeenan U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007;40:1144-1151.
15. Zimmermann EA, Schaible E, Baile H, et al. Age-related changes in the plasticity and toughness of human cortical bone at multiple length scales. Proc Natl Acad Sci USA 2011;108:14416-14421.
16. Wang G, Sai L, Gai P, et al. The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment: which therapies work best? a network meta-analysis. Bone Joint Res 2017;6:452-463.
17. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a network meta-analysis. Bone 2004;34:1241-1249.
18. Metz TJ, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003;419:41-49.
19. Usha R, Jaimohan SM, Rajaram A, Mandal AB. Aggregation and self assembly of non-enzymatic glycation of collagen in the presence of amino guanidine and asparagine: an in vitro study. Int J Biol Macromol 2010;46:402-409.
20. Booth AA, Khalilah RG, Todd P, Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Andoramic glycation pathways. J Biol Chem 1997;272:5430-5437.
21. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1988;13:763-773.
22. Hemmerich KJ. General aging theory and simplified protocol for accelerated aging of medical devices. Med Plas Biomat 1988;5:16-23.
23. Hukins DWL, Mahomed A, Kukurenak SN. Accelerated aging for testing polymeric biomaterials and medical devices. Med Eng Phys 2008;30:1270-1274.
24. Vashishth D, Gibson GJ, Khoury JI, et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001;28:195-201.
25. Vashishth D. Collagen glycation and its role in fracture properties of bone. J Musculoskeletal Neuronal Interact 2005;5:316.
26. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003;419:31-40.
27. Stitt A, Gardiner TA, Alderson NL, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002;51:2626-2632.
28. Gallant MA, Brown DM, Organ JM, Allen MR, Burr DB. Reference-point indentation correlates with bone toughness assessed using whole-bone traditional mechanical testing. Bone 2013;53:301-305.
29. Hansma P, Yu H, Schultz D, et al. The tissue diagnostic instrument. Rev Sci Instrum 2008;80:054303.
30. Abraham AC, Agarwalla A, Yadavalli A, et al. Multiscale predictors of femoral neck in situ strength in aging women: contributions of BMD, cortical porosity, reference point indentation, and nonenzymatic glycation. J Bone Miner Res 2015;30:2207-2214.
31. Diez-Perez A, Guerri R, Nogues X, et al. Microindentation for in vivo measurement of bone tissue mechanical properties in humans. J Bone Miner Res 2010;25:1877-1885.
32. Tang SY, Vashishth D. Non-enzymatic glycation alters microdamage formation in human cancellous bone. Bone 2010;46:148-154.
33. Valcourt U, Merle B, Gineys E, et al. Non-enzymatic glycation of bone collagen modifies osteoelastic activity and differentiation. J Biol Chem 2007;282:5691-5703.
34. Allen MR, Burr DB. Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs. Osteoporos Int 2008;19:95-99.
35. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-1249.
36. Giusti A, Handy NA, Dekkers OM, et al. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011;48:966-971.
37. Alam S, Ahsan A, Alam S. Newer insights in drugs inhibiting formation and accumulation of advanced glycation end products. J Biomol Technol 2013;5:666-672.
38. Nagaraj RH, Sarkar P, Mally A, et al. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch Biochem Biophys 2002;402:110-119.
39. Verzijl N, DeGroot J, Oldehinkel E, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000;350:381-387.
40. Fuehrer R, Aminoguanidine, et al. Use of aminoguanidine to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003;419:41-49.
41. Brownlee M, Vissers S, Kooi P, Ulrich P, Cerami A. Advanced glycation prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-1632.

Funding Statement

Funding provided by WUSTL Musculoskeletal Research Center, NIH P30 AR57325, NIH R43 AG060607, K01 AR069116, and R21 AR069804

Author Contributions

O. Abar: Designing the study, Obtaining and preparing study samples, Performing all aspects of protein assays and mechanical testing, Analyzing and interpreting the data, Writing the manuscript.
S. Dharmar: Participating in the design of the study, Providing guidance in all aspects of the protein assays and mechanical testing.
S. Tang: Designing the study, Providing guidance in all aspects of protein assays and mechanical testing, Analyzing and interpreting the data, Writing the manuscript.

Conflict of Interest Statement

None declared © 2018 Abar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution licence (CC-BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, but not for commercial gain, provided the original author and source are credited.